background and aim. There is a lack of recent epidemiological studies on recurrent stroke (RS) in Poland. The aim of this study was to analyse all hospitalisations related to RS in Silesia -an industrial region covering 12% of the Polish population.
Introduction
Stroke constitutes the third highest cause of death and the main cause of permanent disability in adults in Europe. Due to its poor prognosis, and the high costs of treatment and of chronic care, stroke is not only a medical but also a social problem.
Recently conducted epidemiological studies have significantly improved our understanding of stroke epidemiology and treatment. But regular updates at local, national and global levels are needed. The first epidemiological data on cerebrovascular diseases in Poland comes from the years 1980-2010 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . The most recent studies, both national and regional, were conducted in the last decade [14] [15] [16] [17] . Some of them have concerned the Silesian Province, an industrial region of Poland covering 12% of the nation's population (4.6 million people). In these studies, we have analysed the local incidence of first-ever-stroke (FS), the number of stroke hospitalisations, stroke aetiology, outcome, used methods of diagnostics, and treatment between 2009 and 2015 [15, 16] .
However, there is still a lack of recent epidemiological data on recurrent stroke (RS) in Poland despite the fact that this is a known indicator of the effectiveness of secondary stroke prevention.
Therefore, the aim of this study was to assess the epidemiological characteristics of RS in the Silesian Province of Poland over the course of the last decade.
Materials and methods
Our study was based on data obtained from stroke questionnaires (n = 88,425) which were mandatorily reported to the National Health Fund (NHF; the only public health insurer in Poland) by all Silesian hospital departments for stroke patients (homogeneous patient groups: A48-A51). The analysed period was between 2009 and 2015. The study was carried out with the approval of the Silesian division of the NHF and the Consultant in Neurology for the Silesian Province.
The questionnaire was verified for incomplete or recurring data (e.g. recurring records of the same hospitalisation were excluded). Finally, 81,193 stroke questionnaires were enrolled for analysis. A diagnosis of stroke was made according to the International Classification of Diseases version 10 (ICD-10).
The following data from the stroke questionnaires were used in the present study: age, sex, admission date, date of the first occurrence of stroke symptoms, date of death or discharge, number of hospitalisation days, aetiology of ischaemic stroke (IS) (according to the Trial Org 10172 in Acute Stroke Treatment -TOAST), clinical symptoms (consciousness disorders, hemiparesis/hemiplegia, speech disorders, sensory disorders, posterior circle syndrome), secondary stroke prevention (antiplatelets, anticoagulants, antihypertensives), information on referral for vascular intervention due to artery stenosis, and application of recombinant tissue plasminogen activator (rtPA).
The questionnaires also included information as to whether the stroke was classified as first-ever-stroke (FS) or recurrent stroke (RS). FS was diagnosed when the response to the question "Was it your first stroke accident?" was "Yes", and RS when the response was "No".
According to the Bioethics Committee, the study was not a medical experiment. Therefore, no approval of the Committee was required.
Statistical analysis was done using SAS statistical package version 9.4 (SAS Institute Inc., Cary, NC, USA). The level of statistical significance was set at p < 0.05.
For nominal data, percentage values were used. The correlation between the nominal variables was verified using the χ2 test. Normally distributed quantitative data were characterised using the mean and the standard deviation, whereas the median and the interquartile range was used for non-normally distributed data. The verification of the distribution of the variables and the agreement with the normal distribution were made using the Shapiro-Wilk test. The mean difference significance was verified using the Student's t-test for two groups and the ANOVA test for three or more groups. The consistency of the distribution was verified using the Mann--Whitney U test for two groups and the Kruskal-Wallis test for three or more groups for skewed distributions. Multiple comparisons were made based on post-hoc test results for variance analysis (ANOVA) and the Kruskal-Wallis test and with the Holm-Bonferroni correction to assess significance of the percentage difference in cases of three or more groups. The test for trend was also calculated for consecutive years by means of Jonckheere-Terpstra and Cochran-Armitage tests for continuous and categorical variables, respectively.
Results
Based on analysis of the data obtained from the stroke questionnaires, the number of RS hospitalisations in the Silesian Province between 2009 and 2015 was 18,063 (9,229 women and 8,715 men; P < 0.001; in 119 cases sex was not recorded). In 4,763 subjects, the type of stroke (first or recurrent) could not be determined (Tab. 1).
RS constituted 22.2% of all acute stroke hospitalisations in the analysed period. The number of hospitalisations due to recurrent haemorrhagic stroke (RHS; I60, I61, I62) was 1,619 (15% of all hospitalisations with acute haemorrhagic stroke i.e. HS diagnosis), while the total number of hospitalisations due to recurrent ischaemic stroke (RIS; I63) was 16,256 (23.4% all hospitalisations with acute IS diagnosis) (Tab. 3, 4) .
The percentage of RS significantly decreased during the period under consideration (p < 0.001). The same observation concerned RIS, but not RHS (Tab. 1, 3, 4) .
The median age for patients with RS was 74 (range 66-81) years. The age of male patients (71 (range 63-78) years) was statistically significantly lower (P < 0.001) compared to female patients (78 (70-84) years).
The median age for patients with RIS was 75 (range 66-81) years. The age of male patients (71 (range 63-79) years) was statistically significantly lower (P < 0.001) compared to female patients (78 (range 70-84) years).
The median age for patients with RHS was 72 (range 62-80) years. The age of male patients (69 (range 61-77) years) was statistically significantly lower (P < 0.001) compared to female patients (76 (range 66-82) years) (Tab. 5).
Large-artery atherosclerosis and cardioembolisms were significantly more often recognised in RIS than in first-ever ischaemic stroke (FIS) (consecutively, 38.2% vs 36.0%, and 21% vs 18.1%; p < 0.001). On the other hand, lacunar stroke was less All -all stroke types (I60-I64); FS -first-ever-stroke; RS -recurrent stroke; ND -no data on type of stroke; a -Cochran-Armitage test for trend with Holm-Bonferroni correction often diagnosed in RIS than in FIS (8.8% vs 10.0%; p < 0.001). The aetiology of stroke was undetermined in 30.4% of subjects of RIS compared to 34.1% of subjects of FIS (p < 0.001) (Tab. 6).
The clinical manifestation of stroke was significantly more expressed in RIS than in FIS (p < 0.001) (Tab. 7). During the analysed period, the in-hospital mortality rate for RS was 18.4%, and it was significantly higher compared to FS (17.2%) (p < 0.001). The same observation was done for RIS vs FIS (16.2% vs 13.9%; p < 0.001), and for RHS vs first-ever haemorrhagic stroke (FHS) (39.8% vs 36%; p = 0.004). The same trend was seen in women and in men (Tab. 8-10).
The median hospitalisation time was 14 (range 5-24) days for RHS, and 11 (range 9-15) days for RIS (Tab. 11). 77.2% of patients with FS and 78.9% of patients with RS were admitted to hospital on the day when stroke symptoms appeared (p < 0.001).
The rtPA therapy was applied to 2,598 patients with FIS (5.3%) and to 525 patients with RIS (3.2%) treated in hospitals of the Silesian Province between 2009 and 2015 (p < 0.001) (Tab. 2). The percentage changed between 2009 and 2015 from 1.3% (FIS) and 0.7% (RIS) to 10.3% (FIS) and 6.7% (RIS).
The overall in-hospital mortality in patients with FIS treated with rtPA (n = 396; 15.2%) was not statistically significantly higher compared to the in-hospital mortality of patients with FIS untreated with rtPA (n = 6,489; 13.9%) (P = 0.142). Also, the overall in-hospital mortality in patients with RIS treated with rtPA (n = 87; 16.6%) was not statistically significantly higher compared to the in-hospital mortality of patients with RIS untreated with rtPA (n = 2,548; 16.2%) (P = 0.885). No difference was found between the in-hospital mortality of FIS patients and the in-hospital mortality of RIS patients treated with rtPA (p = 0.885). Gender did not influence the in-hospital mortality in patients treated with rtPA (Tab. [12] [13] .
The in-hospital mortality in patients either with RIS or FIS was significantly higher in cardiogenic stroke compared to atherogenic stroke (Tab. [14] [15] .
The in-hospital mortality in patients either with FIS or RIS treated with rtPA was not associated with aetiology of stroke (Tab. [16] [17] .
Data obtained from the stroke questionnaires allowed us to determine the secondary stroke prevention therapy; 81.7% of RIS patients and 84.3% of FIS patients (p < 0.001) were administered antiplatelet drugs, 26.2% of RIS subjects and 23% of FIS subjects -oral anticoagulants (p < 0.001), and subsequently, 84.4% and 79.9% -antihypertensive drugs (p < 0.001) (Tab. 18). Furthermore, 3.4% of patients with FIS and 3.1% of patients with RIS were referred for vascular intervention due to artery stenosis.
In patients with cardioembolic stroke aetiology, 37.5% of subjects with FIS and 40.6% of subjects with RIS were administered anticoagulants. The percentage of patients with RIS and cardioembolic stroke treated with anticoagulants gradually increased over the subsequent years (p = 0.033) while a negative trend was observed for antiplatelet drugs (p = 0.004) (Tab. 19 ).
Discussion
As we described in our previous paper, the number of hospitalisations due to stroke and the incidence of first-ever--stroke in the Silesian Province were high (from 169/100,000 in 2009 to 187/100,000 in 2015), and seemed to be more akin to Eastern rather than to Western European countries [15, 18, 19] . This suggests that primary prevention of stroke may be imperfectly implemented in our country, and that the awareness of cerebrovascular risk factors is insufficient.
On the other hand, the number of recurrent strokes is the indictor of the efficiency of secondary prevention. Our study shows that hospitalisations due to recurrent stroke constituted a little more than one fifth of all hospitalisations due to acute stroke. The recurrence is higher in IS than in HS. The selected epidemiological studies show that the risk of recurrence after a first-ever stroke reaches 4% at 1 month, 13% at 1 year, and almost 40% at 10 years [20] [21] [22] [23] [24] . Readmission to hospital has a negative effect on the quality of a patient's life and increases socioeconomic costs [25] .
We have found that the number of RS has significantly decreased during the last decade (RS constituted 23.1% of all stroke hospitalisations in 2009 but 20.1% in 2015; p < 0.001). In the Warsaw Stroke Registry (conducted in 1991-1992), recurrent strokes constituted 27% of all acute stroke events observed during the study [2, 3] . In our study, a decreasing number concerned RIS, but not RHS. This is consistent with other studies [20, 26] . The decreasing number of recurrent strokes could be associated with a better stroke care network and improvements in secondary stroke prevention. This is also consistent with the observation that the number of stroke survivals with atrial fibrillation on anticoagulants increased from 40% in 2009 to 44% in 2015.
As regards the aetiology of RIS, this was undetermined in less than one third of patients (for comparison, in 1991-1992 this figure was more than half) [2, 3] . Such a decrease in unknown aetiology might be the result of a greater availability of diagnostic methods (such as ultrasonography, magnetic resonance, angiography, and broader cardiologic diagnostic possibilities). It is worth emphasising that undetermined RIS was rarer than undetermined FIS (30% vs 34%). The most common reason for RIS was large-artery atherosclerosis. Cardioembolisms were responsible for 21% of RIS (18% in FIS).
In our study we could not establish the recurrence rates for different subtypes of ischaemic stroke because the findings were anonymous. From the literature, we can see that FHS -first-ever haemorrhagic stroke (I60-I62); RHS -recurrent haemorrhagic stroke (I60-I62); ND -no data; a -Cochran-Armitage test for trend with Holm-Bonferroni correction the 3-month recurrence rates are higher for stroke caused by large artery atherosclerosis (14.3%) than for cardioembolic stroke (7.7%), lacunar stroke (2%) and ischaemic stroke due to undetermined causes (5.6%) [27] . A 23-year longitudinal population-based study showed that the implementation of a stroke care network and good primary prevention are defined areas associated with a decrease in the number of recurrent strokes [26] .
The clinical symptoms were significantly more expressed in RIS than in FIS. Similarly to other authors, we found that hemiparesis/hemiplegia and speech disorders were the most common presenting symptoms [28] .
The median length of hospital stay was 11 (range 9-15) days for RIS and 14 (range 5-24) days for RHS, both shorter than previously described [29] . Hospitalisation time was similar for RIS and FIS, but longer for RHS than for FHS. FS -first-ever stroke; RS -recurrent stroke; FIS -first-ever ischaemic stroke (I63); RIS -recurrent ischaemic stroke (I63); FHS -first-ever haemorrhagic stroke (I60-I62); RHS -recurrent haemorrhagic stroke (I60-I62) Lekoubou et al. observed that stroke survivors had a 43% higher risk of dying after a RS compared to those with FS, because of unfavourable stroke risk profile [30] . In our study, the in-hospital mortality rate was also significantly higher for RS than for FS (18.4% vs 17.2%; p < 0.001). The same finding concerned RIS vs FIS (16.2% vs 13.9%; p < 0.001), and RHS vs FHS (39.8% vs 36%; p = 0.004). This might be also associated with older age and more expressed clinical symptoms in patients with RS.
We found that the rtPA therapy was applied to a smaller percentage of RIS patients (in 2009 -0.7%; in 2015 -6.7%) than FIS patients (in 2009 -1.3%; in 2015 -10.3%).
In some Western European countries, the percentage of patients with IS treated with rtPA was higher than in the Silesian Province e.g. up to 35% in the German state of Hesse (2007-2008) [31] [32] [33] . Silesia has a dense urban infrastructure and the densest hospital network in Poland, so transportation seems not to be a problem. In our opinion, the main reason for the low percentage of patients treated with rtPA in the Silesian Province remains insufficient knowledge and social awareness of stroke symptoms and the possibilities of treatment [34, 35] . Educational programmes should be regularly conducted among people using all forms of modern media.
Conclusions

1.
Recurrent strokes constituted about one fifth of all stroke hospitalisations. However, the recurrence rate of ischaemic stroke has systematically decreased over the last decade. This is evidence of better secondary stroke prevention. 2. Large-artery atherosclerosis and cardioembolisms were significantly more often recognised in RIS than in FIS, but the main reason for RIS was large artery atherosclerosis. 3. The in-hospital mortality rate was significantly higher for RS than for FS. 4. Patients with RIS were almost two times less often treated with rtPA than patients with FIS. 5. This was the first such comprehensive analysis of RS in the Silesian Province, Poland. This study could help in the implementation of appropriate educational programmes, and thus help to improve the health status of society.
Limitations of the study
There were a few limitations to this research, as described in previous studies [15, 16] . Firstly, in our paper we analysed only stroke-related hospitalisations, but in Poland almost all patients with AS are admitted to hospital. Secondly, it is possible that in the case of some ASs the questionnaires might not have been sent to the NHF. Thirdly, we could not estimate the number of stroke-related deaths that had occurred prior to the patient's arrival at hospital, and therefore the true hospitalised incidence of stroke might be underestimated. Fourthly, we only analysed the questionnaire data and the information those questionnaires contained. As a result, human error could have occurred. Fifthly, the data was anonymous so we could not analyse the trends for strokes.
